New therapies for nontuberculous mycobacterial lung infection

Sarah J. Chalmers; Timothy R. Aksamit

doi:10.1097/QCO.0000000000000815

New therapies for nontuberculous mycobacterial lung infection

Sarah J. Chalmers, Timothy R. Aksamit

Pulmonary and Critical Care Medicine

Research output: Contribution to journal › Review article › peer-review

Abstract

Purpose of reviewAlthough nontuberculous mycobacterial pulmonary disease is increasing in incidence, outcomes remain less than optimal highlighting the unmet need for developing novel therapies.Recent findingsSeveral new antibiotic formulations, novel antibiotics, and novel nonantibiotic treatments have recently demonstrated positive results in treating nontuberculous mycobacterial pulmonary disease.SummaryPromising novel therapies are currently under investigation fueling much needed interest and enthusiasm in the nontuberculous mycobacterial pulmonary disease space and will hopefully lead to improved understanding and outcomes in this complex disease.

Original language	English (US)
Pages (from-to)	176-184
Number of pages	9
Journal	Current Opinion in Infectious Diseases
Volume	35
Issue number	2
DOIs	https://doi.org/10.1097/QCO.0000000000000815
State	Published - Apr 1 2022

Keywords

antibacterial agents
bacteriophages
lung disease
nontuberculous mycobacteria
therapy

ASJC Scopus subject areas

General Medicine

Access to Document

10.1097/QCO.0000000000000815

Cite this

@article{16da6c03abae4dafae93acbe7d6dcc49,

title = "New therapies for nontuberculous mycobacterial lung infection",

abstract = "Purpose of reviewAlthough nontuberculous mycobacterial pulmonary disease is increasing in incidence, outcomes remain less than optimal highlighting the unmet need for developing novel therapies.Recent findingsSeveral new antibiotic formulations, novel antibiotics, and novel nonantibiotic treatments have recently demonstrated positive results in treating nontuberculous mycobacterial pulmonary disease.SummaryPromising novel therapies are currently under investigation fueling much needed interest and enthusiasm in the nontuberculous mycobacterial pulmonary disease space and will hopefully lead to improved understanding and outcomes in this complex disease.",

keywords = "antibacterial agents, bacteriophages, lung disease, nontuberculous mycobacteria, therapy",

author = "Chalmers, {Sarah J.} and Aksamit, {Timothy R.}",

year = "2022",

month = apr,

day = "1",

doi = "10.1097/QCO.0000000000000815",

language = "English (US)",

volume = "35",

pages = "176--184",

journal = "Current Opinion in Infectious Diseases",

issn = "0951-7375",

publisher = "Lippincott Williams and Wilkins",

number = "2",

}

TY - JOUR

T1 - New therapies for nontuberculous mycobacterial lung infection

AU - Chalmers, Sarah J.

AU - Aksamit, Timothy R.

PY - 2022/4/1

Y1 - 2022/4/1

N2 - Purpose of reviewAlthough nontuberculous mycobacterial pulmonary disease is increasing in incidence, outcomes remain less than optimal highlighting the unmet need for developing novel therapies.Recent findingsSeveral new antibiotic formulations, novel antibiotics, and novel nonantibiotic treatments have recently demonstrated positive results in treating nontuberculous mycobacterial pulmonary disease.SummaryPromising novel therapies are currently under investigation fueling much needed interest and enthusiasm in the nontuberculous mycobacterial pulmonary disease space and will hopefully lead to improved understanding and outcomes in this complex disease.

AB - Purpose of reviewAlthough nontuberculous mycobacterial pulmonary disease is increasing in incidence, outcomes remain less than optimal highlighting the unmet need for developing novel therapies.Recent findingsSeveral new antibiotic formulations, novel antibiotics, and novel nonantibiotic treatments have recently demonstrated positive results in treating nontuberculous mycobacterial pulmonary disease.SummaryPromising novel therapies are currently under investigation fueling much needed interest and enthusiasm in the nontuberculous mycobacterial pulmonary disease space and will hopefully lead to improved understanding and outcomes in this complex disease.

KW - antibacterial agents

KW - bacteriophages

KW - lung disease

KW - nontuberculous mycobacteria

KW - therapy

UR - http://www.scopus.com/inward/record.url?scp=85125883379&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85125883379&partnerID=8YFLogxK

U2 - 10.1097/QCO.0000000000000815

DO - 10.1097/QCO.0000000000000815

M3 - Review article

C2 - 34966084

AN - SCOPUS:85125883379

SN - 0951-7375

VL - 35

SP - 176

EP - 184

JO - Current Opinion in Infectious Diseases

JF - Current Opinion in Infectious Diseases

IS - 2

ER -

New therapies for nontuberculous mycobacterial lung infection

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this